National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 65 of 66
Paclitaxel Plus Topotecan in Treating Patients With Solid Tumors
NCT00002587
A Case-Referent Study of Brain Tumors in Adults
NCT00339300
Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma
NCT00002556
Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus Infection
NCT00001386
Positron Emission Tomography in Patients With Breast Cancer
NCT00001385
A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients
NCT00001384
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
NCT00001383
A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate
NCT00001382
A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder
NCT00001381
A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer
NCT00001378
A Pilot Study of Topical Antiflammin-2 for Psoriasis
NCT00001371
Familial Prostate Cancer
NCT00001377
Retinoblastoma Biomarker Study
NCT00342797
Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate
NCT00018967
Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer
NCT00002537
A Phase I Trial of ZD1694 (TOMUDEX), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease
NCT00001341
A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection
NCT00001339
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer
NCT00001338
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
NCT00001337
In Vitro Study of Peripheral Blood Mononuclear Cell Function in Healthy Individuals and Patients
NCT00342485
New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma
NCT00001335
In Vitro Studies of Immunological and Stem Cell Function in Peripheral Blood Mononuclear Cells in Patients
NCT00001336
Phase I Study of Intrathecal Topotecan
NCT00001333
Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis
NCT00001332
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
NCT00001302
Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors
NCT00001301
A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma
NCT00001300
A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction
NCT00001298
Study of Scaling Disorders and Other Inherited Skin Diseases
NCT00001292
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma
NCT00001296
Continuing Care and Treatment for Patients With Cancer/AIDS/Skin Disease
NCT00001295
Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi's Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens
NCT00001294
A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Previously Nontreated Ovarian Cancer Patients
NCT00001272
A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
NCT00001271
Polyp Prevention Trial
NCT00339625
Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma
NCT00001270
Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer
NCT00001269
Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
NCT00018941
A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma
NCT00001266
A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-Dideoxyinosine
NCT00001267
Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial
NCT00001250
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac
NCT00001249
Phase I Study of Intrathecal Mafosfamide
NCT00001251
Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer
NCT00001239
Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas
NCT00001237
Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study
NCT00001217
Prediction and Testing of Antigenic Sites of the AIDS Virus, HTLV-III Recognized by T Lymphocytes for the Development of Synthetic Vaccines
NCT00001210
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
NCT00001209
A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer
NCT00001193
The Role of Multi-Modality Therapy for the Treatment of High-Grade Soft Tissue Sarcomas of the Extremities
NCT00001188
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.